Growth Hormone Axis · GHRH analog + GH secretagogue (compounded)
CJC-1295 + Ipamorelin
- Drug class
- GHRH analog + GH secretagogue (compounded)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What CJC-1295 + Ipamorelin is studied for
- Growth hormone axis support
- Sleep quality and slow-wave sleep
- Body composition and recovery
- Adult IGF-1 optimization (off-label)
Mechanism of action
CJC-1295 (mod-GRF 1-29 or DAC variant) binds GHRH receptors to amplify endogenous GH release. Ipamorelin binds the ghrelin/GHSR receptor to trigger a clean GH pulse — selectively, without cortisol or prolactin rise (unlike older GHRPs).
Frequently asked questions
How is CJC-1295 + Ipamorelin dosed?
Typical research dosing is 100–300 mcg of each, subcutaneously, 1–3x daily — most commonly at bedtime to align with the largest natural GH pulse. Always under clinician supervision.
Will it shut down natural GH?
Unlike exogenous HGH, GHRH + GHRP combinations work with the pituitary, preserving negative-feedback safety. Cycling is still commonly recommended.
What is the difference between CJC with DAC and no DAC?
No DAC ("Mod GRF 1-29") has a short half-life — clean pulses. With DAC (drug affinity complex) extends half-life to ~8 days, producing sustained GH elevation rather than pulses. Most clinical protocols favor no-DAC for safety.
Side effects?
Injection-site reactions, transient flushing, increased appetite, occasional tingling. Long-term human safety data is limited.